<DOC>
	<DOC>NCT00742820</DOC>
	<brief_summary>To compare the bioequivalence of calcium acetate oral solution vs. calcium acetate gelcaps in healthy volunteers with calcium citrate as a positive control.</brief_summary>
	<brief_title>Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>Signed and dated informed consent form Ages: 1875 years Serum Calcium level 8.610.2 mg/dL 25 vitamin D level 20100 ng/mL 1, 25 dihydroxy vitamin D level 662 pg/mL Fasting glucose level of 6599 mg/dL (min 8 hr fast) iPTH level of 1065 pg/mL Serum phosphorous level of 2.54.5 mg/dL Albumin level of 3.65.1 g/dL Sodium level of 135146 mEq/L Potassium level of 3.55.3 mEq/L Negative pregnancy test (at screening and prior to dosing) for women of childbearing potential and subjects must agree to use adequate contraception (hormonal or double barrier method) during the study No clinically significant abnormalities on electrocardiogram (ECG) reading as determined by the INVESTIGATOR No clinically significant abnormalities on liver function tests No clinically significant abnormalities on CBC and coagulation studies No clinically significant abnormalities on kidney function (eGFR using serum creatinine) BMI between 18.530 Subjects must agree not to consume alcohol while in the treatment phase of the study Women who are pregnant or breast feeding Malignancy except squamous cell carcinoma of the skin Documented current acute or chronic disease Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C Myocardial infarction within 6 months of study Day 0 Parathyroidectomy within 6 months of study Day 0 Gastrointestinal disorder associated with impaired absorption of oral medications Inability to swallow tablets or tolerate calcium acetate oral solution Hormonal therapy (except for contraceptives), immunotherapy or corticoid therapy Concurrent antibiotic treatment Any concurrent investigational treatment within 30 days of screening Unable or unwilling to comply fully with the protocol Diuretic therapy such as Thiazides, Furosemide (INN) or frusemide (former BAN) within one month before screening Subjects taking overthecounter (OTC) or prescribed phosphorous or calcium containing supplements Subjects testing positive for drugs of abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>bioequivalence</keyword>
</DOC>